Doxorubicin inhibits Tat-dependent transactivation of HIV type 1 LTR

AIDS Research and Human Retroviruses

Volumn 12, Issue 7, 1996, Pages 569-576

  Jeyaseelan, Raju ^a   Kurabayashi, Masahiko ^a,b   Kedes, Larry ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PRIORITY JOURNAL; VIRUS ACTIVATION; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0029877318     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.569     Document Type: Article

References (49)

1. Cullen BR: Regulation of HIV-1 gene expression. FASEB J 1991;5:2361-2368.
2. Cullen BR: Regulation of human immunodeficiency virus replication. Annu Rev Microbiol 1991;45:219-250.
3. Dayton AI, Sodroski JG, Rosen CA, Goh WC, and Haseltine WA: The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 1986;44:941-947.
4. Haseltine WA: Molecular biology of the human immunodeficiency virus type 1. FASEB J 1991;5:2349-2360.
5. Kam J: Control of human immunodeficiency virus replication by the tat, rev, nef and protease genes. Curr Opin Immunol 1991;3:526-536.
6. Pavlakis GN and Felber BK: Regulation of expression of human immunodeficiency virus. New Biologist 1990;2:20-31.
7. Steffy K and Wong SF: Genetic regulation of human immunodeficiency virus. Microbiol Rev 1991;55:193-205.
8. Arya SK, Guo C, Josephs SF, and Wong-Staal F: Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985;229:69-73.
9. Sodroski J, Rosen C, Wong SF, Salahuddin SZ, Popovic M, Arya S, Gallo RC, and Haseltine WA: Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science 1985;227:171-173.
10. Kato H, Sumimoto H, Pognonec P, Chen CH, Rosen CA, and Roeder RG: HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors. Genes Develop 1992;6:655-666.
11. Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R, and Gaynor RB: Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J 1989;8:765-778.
12. Selby MJ, Bain ES, Luciw PA, and Peterlin BM: Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. Genes Dev 1989;3:547-558.
13. Guarner J, del-Rio C, Carr D, Hendrix LE, Eley JW, and Unger ER: Non-Hodgkin's lymphomas in patients with human immunodeficiency virus infection. Presence of Epsten-Barr virus by in situ hybridization, clinical presentation, and follow-up. Cancer 1991;68:2460-2465.
14. Levine AM, Wernz JC, Kaplan L, Rodman N, Cohen P, Metroka C, Bennett JM, Rarick MU, Walsh C, Kahn J, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial [see comments]. JAMA 1991;266:84-88.
15. Schneider AM, Straus DJ, Schluger AE, Lowenthal DA, Koziner B, Lee BJ, Wong G, and Clarkson BD: Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas. J Clin Oncol 1990;8:94-102.
16. Schuermann D, Dienemann D, Jautzke G, Cervos NJ, Langford A, Stein H, Pohle HD, and Ruf B: Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases. Klin Wochenschrift 1991;69:679-686.
17. Tirelli U, Errante D, Oksenhendler E, Spina M, Vaccher E, Serraino D, Gastaldi R, Repetto L, Rizzardini G, Carbone A, et al.: Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group. Ann Oncol 1992;3:843-847.
18. Walsh C, Wernz JC, Levine A, Rarick M, Wilson E, Melendez D, Bonnem E, Thompson J, and Shelton B: Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. J Acq Immune Defic Synd 1993;6:265-271.
19. Nakashima H, Yamamoto N, Inouye Y, and Nakamura S: Inhibition by doxorubicin of human immuno-deficiency virus (HIV) infection and replication in vitro. J Antibiot 1987;40:396-399.
20. Bergamini A, Perno CF, Balzarini J, Capozzi M, Calio R, and Rocchi G: Adriamycin selectively inhibits HIV replication in resting macrophages. Int Conf AIDS 1991;7:109 (abstract W.A. 1071).
21. Perno CF, Yarchoan R, Balzarini J, Bergamini A, Milanese G, Pauwels R, De Clercq E, Rocchi G, and Calio R: Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiviral Res 1992;17:289-304.
22. Gorman CM, Moffat LF, and Howard BH: Recombinant genomes which express chloramphenicol acetyl transferase in mammalian cells. Mol Cell Biol 1981;2:1044-1051.
23. Sartorelli V, Webster KA, Lassar AB, and Kedes LH: The MyoD1 gene product trans-activates and binds to the human cardiac α-actin promoter. In: Sardinia Symposium on Advances in Biotechnology, Control of Gene Expression. University of Sassari, Alghero, Italy, 1989.
24. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976;72:248-254.
25. Peterlin BM, Luciw PA, Barr PJ, and Walker MD: Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus. Proc Natl Acad Sci USA 1986; 83:9734-9738.
26. Chang LJ, McNulty E, and Martin M: Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. J Virol 1993;67:743-752.
27. Kuppuswamy M, Subramanian T, Srinivasan A, and Chinnadurai G: Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res 1989;17:3551-3561.
28. Rhim H and Rice AP: TAR RNA binding properties and relative transactivation activities of human immunodeficiency virus type 1 and 2 Tat proteins. Virol 1993;67:1110-1121.
29. Garcia JA, Wu FK, Mitsuyasu R, and Gaynor RB: Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J 1987;6:3761-3770.
30. Southgate CD and Green MR: The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: Implications for Tat function. Genes Develop 1991;5:2496-2507.
31. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl K: eds. Current Protocol in Molecular Biology. Greene Publishing and John Wiley & Sons, New York, 1991.
32. Kurabayashi M, Jeyaseelan R, and Kedes L: Antineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts. J Biol Chem 1993;268:5524-5529.
33. Kurabayashi M, Jeyaseelan R, and Kedes L: Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor MyoD. J Biol Chem 1994;269:6031-6039.
34. Kamine J, Subramanian T, and Chinnadurai G: Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1991;88:8510-8514.
35. Selby MJ and Peterlin BM: Trans-activation by HIV-1 Tat via a heterologous RNA binding protein. Cell 1990;62:769-776.
36. Roy S, Delling U, Chen CH, Rosen CA, and Sonenberg N: A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev 1990;4:1365-1373.
37. Harper JW and Logsdon NJ: Refolded HIV-1 tat protein protects both bulge and loop nucleotides in TAR RNA from ribonucleolytic cleavage. Biochemistry 1991;30:8060-8066.
38. Zhang H, Gao YG, vander Marel GA, van Boom JH, and Wang AH: Simultaneous incorporations of two anticancer drugs into DNA. The structures of formaldehyde-cross-linked adducts of daunorubicin-d(CG(araC)GCG) and doxorubicin-d(CA(araC)GTG) complexes at high resolution. J Biol Chem 1993;268:10095-10101.
39. Gaynor R: Cellular transcription factors involved in the regulation of HIV-1 gene expression. Aids 1992;6:347-363.
40. Wu F, Garcia J, Sigman D, and Gaynor R: Tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev 1991;5:2128-2140.
41. Carrier F, Gatignol A, Hollander MC, Jeang K-T, and Fornace AJ Jr: Induction of RNA-binding proteins in mammalian cells by DNA-damaging agents. Proc Natl Acad Sci USA 1994;91: 1554-1558.
42. Nelbock P, Dillon PJ, Perkins A, and Rosen CA: A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator. Science. 1990;248:1650-1653.
43. Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, and Volsky DJ: Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 1991;254:1799-1802.
44. Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, and Volsky DJ: Discovery and characterization of an HIV-1 Tat antagonist. Biochem Soc Trans 1992;20:525-531.
45. Hsu MC, Dhingra U, Earley JV, Holly M. Keith D, Nalin CM, Richou AR, Schutt AD, Tam SY, Potash MJ, et al.: Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc Natl Acad Sci USA 1993;90:6395-6399.
46. Braddock M, Cannon P, Muckenthaler M, Kingsman AJ, and Kingsman SM: Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in xenopus oocytes by the Benzodiazepine Ro24-7429 requires trans-ativation response element loop sequences. J Virol 1994;68:25-33.
47. Li CJ, Wang C, and Pardee AB: Camptothecin inhibits Tat-mediated transactivation of type 1 human immunodeficiency virus. J. Biol. Chem. 1994;269:7051-7054.
48. Cummings J and Smyth JF: DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 1993;4:533-543.
49. Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, and Valentine ES: Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: A highly active regimen. Blood 1993; 81:2810-2815.